ASMB Logo

Assembly Biosciences Inc (ASMB) Stock Forecast & Price Prediction

Live ASMB Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$14.21

+0.40 (2.90%)

12 Month Price Forecast For ASMB

$14.21
Current Price
$90.32M
Market Cap
3 Ratings
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to ASMB Price Forecasts

+153.3%
To High Target of $36.00
+149.8%
To Median Target of $35.50
+146.3%
To Low Target of $35.00

ASMB Price Momentum

-1.5%
1 Week Change
-18.1%
1 Month Change
+15.0%
1 Year Change
-9.9%
Year-to-Date Change
-28.7%
From 52W High of $19.93
+44.4%
From 52W Low of $9.84

๐Ÿค” Considering Assembly Biosciences (ASMB)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 6, 2025 11:09 AM UTC

ASMB Analyst Ratings & Price Targets

Based on our analysis of 7 Wall Street analysts, ASMB has a consensus that is bullish. The median price target is $35.50, with forecasts ranging from $35.00 to $36.00. Currently, there are 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings.

With ASMB currently trading at $14.21, the median price forecast suggests a 149.8% upside. The most optimistic forecast comes from at , projecting a 153.3% upside, while Dennis Ding at Jefferies provides the most conservative target, suggesting a 146.3% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ASMB Analyst Consensus

2
Buy
1
Hold
0
Sell

ASMB Price Target Range

Low
$35.00
Average
$35.50
High
$36.00
Current: $14.21

Latest ASMB Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ASMB.

Date Firm Analyst Rating Change Price Target
Dec 27, 2024 HC Wainwright & Co. Ed Arce Neutral Reiterates $0.00
Sep 24, 2024 HC Wainwright & Co. Ed Arce Neutral Reiterates $0.00
Sep 20, 2024 Jefferies Dennis Ding Buy Upgrade $35.00
Jun 20, 2024 HC Wainwright & Co. Ed Arce Neutral Reiterates $0.00
Jun 13, 2024 HC Wainwright & Co. Ed Arce Neutral Reiterates $0.00
Apr 1, 2024 HC Wainwright & Co. Ed Arce Neutral Reiterates $0.00
Mar 24, 2023 HC Wainwright & Co. Ed Arce Neutral Maintains $1.50
Nov 16, 2022 Mizuho Salim Syed Buy Maintains $3.00
Oct 24, 2022 Truist Securities Nicole Germino Hold Downgrade $2.00
Apr 1, 2022 Truist Securities Nicole Germino Buy Maintains $12.00
Sep 13, 2021 HC Wainwright & Co. Neutral Initiates $0.00
Sep 2, 2021 William Blair Market Perform Downgrade $0.00
May 10, 2021 SVB Leerink Market Perform Maintains $7.00
Mar 23, 2021 SVB Leerink Geoffrey Porges Market Perform Downgrade $8.00
Nov 6, 2020 Jefferies Hold Downgrade $0.00
Oct 19, 2020 Truist Securities Buy Initiates $0.00
Jul 8, 2020 SVB Leerink Outperform Maintains $38.00
Oct 16, 2019 Mizuho Buy Initiates $0.00
Oct 8, 2018 B. Riley FBR Buy Upgrade $0.00
Oct 8, 2018 B. Riley Securities Madhu Kumar Buy Upgrade $42.00

Stocks Similar to Assembly Biosciences Inc

The following stocks are similar to Assembly Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Assembly Biosciences Inc (ASMB) Financial Data

Assembly Biosciences Inc has a market capitalization of $90.32M with a P/E ratio of -1.1x. The company generates $21.48M in trailing twelve-month revenue with a -212.3% profit margin.

Revenue growth is -19.8% quarter-over-quarter, while maintaining an operating margin of -143.0% and return on equity of -101.8%.

Valuation Metrics

Market Cap $90.32M
Enterprise Value $3.57M
P/E Ratio -1.1x
PEG Ratio -2.0x
Price/Sales 4.2x

Growth & Margins

Revenue Growth (YoY) -19.8%
Gross Margin N/A
Operating Margin -143.0%
Net Margin -212.3%
EPS Growth N/A

Financial Health

Cash/Price Ratio +121.1%
Current Ratio 2.7x
Debt/Equity 5.0x
ROE -101.8%
ROA -34.7%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Assembly Biosciences Inc logo

Assembly Biosciences Inc (ASMB) Company Overview

About Assembly Biosciences Inc

What They Do

Develops therapies for viral diseases.

Business Model

The company focuses on developing therapeutic candidates for viral diseases, particularly targeting herpes simplex virus and hepatitis viruses. It generates revenue through collaboration agreements with other pharmaceutical companies, such as Gilead Sciences and BeiGene, which can provide funding and resources for clinical trials and drug development.

Additional Information

Assembly Biosciences has several promising candidates in various phases of clinical trials, indicating a robust pipeline. The company has a history of changing its name, having been previously known as Ventrus Biosciences, and was incorporated in 2005. Its headquarters is located in South San Francisco, California.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

65

CEO

Mr. Jason A. Okazaki

Country

United States

IPO Year

2010

Assembly Biosciences Inc (ASMB) Latest News & Analysis

ASMB stock latest news image
Quick Summary

ABI-4334 demonstrated a favorable safety profile and a half-life suitable for once-daily oral dosing, indicating potential for regular use in treatment.

Why It Matters

Positive trial results for ABI-4334 suggest strong market potential and may lead to increased sales, enhancing the company's stock value and attracting investor interest.

Source: GlobeNewsWire
Market Sentiment: Neutral
ASMB stock latest news image
Quick Summary

Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have shown performance metrics that can be compared to their respective sector averages for the year.

Why It Matters

Performance comparisons highlight relative strength or weakness in stock price, impacting investment decisions and potential market confidence in Assembly Biosciences and Adma Biologics.

Source: Zacks Investment Research
Market Sentiment: Positive
ASMB stock latest news image
Quick Summary

Data on ABI-5366 and ABI-1179, new long-acting helicase-primase inhibitors for recurrent genital herpes, will be presented soon.

Why It Matters

The presentation of data for ABI-5366 and ABI-1179 could impact stock prices and investor sentiment in the biotech sector, indicating potential breakthroughs in herpes treatment.

Source: GlobeNewsWire
Market Sentiment: Neutral
ASMB stock latest news image
Quick Summary

ABI-5366 is undergoing Phase 1a single ascending dosing trials in healthy participants, with interim data anticipated in Q3 2024.

Why It Matters

The upcoming interim data on ABI-5366 could influence its market potential and investor sentiment, impacting stock prices and future funding opportunities.

Source: GlobeNewsWire
Market Sentiment: Neutral
ASMB stock latest news image
Quick Summary

Assembly Bio presented preclinical data on its helicase-primase inhibitors for genital herpes and a new entry inhibitor for hepatitis D at recent scientific conferences.

Why It Matters

Positive preclinical data for Assembly Bio's herpes and hepatitis D candidates may enhance investor confidence, potentially leading to increased stock value and interest in future clinical trials.

Source: GlobeNewsWire
Market Sentiment: Neutral
ASMB stock latest news image
Quick Summary

Assembly Biosciences, Inc. (Nasdaq: ASMB) reported its financial results for Q1 2024, focusing on its development of therapeutics for serious viral diseases.

Why It Matters

Assembly Biosciences' Q1 financial results may indicate its growth trajectory and effectiveness in developing therapeutics, impacting investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About ASMB Stock

What is Assembly Biosciences Inc's (ASMB) stock forecast for 2025?

Based on our analysis of 7 Wall Street analysts, Assembly Biosciences Inc (ASMB) has a median price target of $35.50. The highest price target is $36.00 and the lowest is $35.00.

Is ASMB stock a good investment in 2025?

According to current analyst ratings, ASMB has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.21. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ASMB stock?

Wall Street analysts predict ASMB stock could reach $35.50 in the next 12 months. This represents a 149.8% increase from the current price of $14.21. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Assembly Biosciences Inc's business model?

The company focuses on developing therapeutic candidates for viral diseases, particularly targeting herpes simplex virus and hepatitis viruses. It generates revenue through collaboration agreements with other pharmaceutical companies, such as Gilead Sciences and BeiGene, which can provide funding and resources for clinical trials and drug development.

What is the highest forecasted price for ASMB Assembly Biosciences Inc?

The highest price target for ASMB is $36.00 from at , which represents a 153.3% increase from the current price of $14.21.

What is the lowest forecasted price for ASMB Assembly Biosciences Inc?

The lowest price target for ASMB is $35.00 from Dennis Ding at Jefferies, which represents a 146.3% increase from the current price of $14.21.

What is the overall ASMB consensus from analysts for Assembly Biosciences Inc?

The overall analyst consensus for ASMB is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $35.50.

How accurate are ASMB stock price projections?

Stock price projections, including those for Assembly Biosciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.